HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Bets On Mexican Private Label Growth With Laboratorios Diba Buy

This article was originally published in The Tan Sheet

Executive Summary

Perrigo is betting the Mexican store-brand market will grow the way private label did in the U.S. 20 years ago, with its $25 million acquisition of Laboratorios Diba

You may also be interested in...



Perrigo Will Acquire Orion Labs To Reach Australian Market

Perrigo's pending $49 million acquisition of Orion Laboratories marks the private labeler's entrance into the promising Australian OTC market and adds a "beachhead" for the firm's continued global expansion, analysts say

People In Brief

Perrigo names VPs: Ron Schutt becomes VP of OTC marketing and Ray Canole VP of corporate development, the Allegan, Mich.-based private-labeler says Feb. 23. Schutt worked for Perrigo for 15 years, most recently as director of marketing for Perrigo's U.S. OTC business. He also served as an analyst with Perrigo's international marketing, pharmaceutical business development and consumer healthcare marketing. Canole joined Perrigo in 2002 as a business development analyst and worked most recently as the senior director of corporate and business development where he managed the acquisitions of JB Labs, Unico and Diba (1"The Tan Sheet" Oct. 13, 2008, p. 3)

Perrigo’s Record OTC Sales Tempered By Rising Costs Of Doing Business

Record OTC drug sales helped boost Perrigo's revenue 29 percent in its latest earnings period, but the rising costs of doing business dragged down margins and forced the company to lower its fiscal 2009 earnings guidance

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel